Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories


Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster

The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.

Cancer Clinical Trials Companies

Another Activist Investor Joins Calls For GSK Leadership Review

A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO, and has underlined competitive threats to a key pipeline candidate.

Companies Commercial Strategy

Novartis Looks To Take Its Diversity Show On The Road

Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.

Diversity & Inclusion Clinical Trials Companies

Coronavirus Spotlight

With Delta Variant Spread, Herd Immunity A ‘Myth’, Says Public Health Expert

Ex-WHO executive and co-chair of the Asia Pacific Immunization Coalition, Tikki Pangestu, outlined at a recent briefing why he believes herd immunity for COVID-19 will not be achievable against the backdrop of the global spread of the highly contagious Delta variant. Facets of vaccine hesitancy and the complexity of vaccine manufacturing were among the other issues discussed by experts.









Coronavirus COVID-19 Vaccines

Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.

Scrip Podcast

Insights and perspectives on commercial, R&D,
deal-making and business strategy developments.

More Podcasts


Recent Tweets from Scrip


 

Infographics

Breast Cancer Trial Enrollment Illustrates Diversity Challenge

INFOGRAPHIC: Data on industry-sponsored breast cancer studies posted on ClinicalTrials.gov shows how much work remains for drug makers to ensure their studies enroll diverse populations.

Diversity & Inclusion Clinical Trials

Alzheimer’s Disease: Many Failures Before One Success

For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over roughly the past decade to showcase exactly how difficult the Alzheimer’s space has been. 

Approvals Clinical Trials

Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration

INFOGRAPHIC: A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.

Leadership Strategy

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

Driving Menarini's Future With Decisive Steps

Two years into her tenure as the head of Menarini, Elcin Barker Ergun has already inked two major cancer deals with the acquisition of Stemline and a key licensing pact with Radius Health. The future for the Italian group is bright, she explained to Scrip in an exclusive interview.

Leadership Business Strategies

Ex-Amgen CIO McKenzie: 'We All Have To Think Like Software Companies'

Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in healthcare and how life science companies can adapt from them while leveraging core capabilities at scale.

Commercial Digital Health

Rhythm Applies Oncology-Like Approach To Genetic Obesity

CEO David Meeker spoke with Scrip about how the company is targeting its drug, Imcivree, across potentially dozens of rare genetic diseases of obesity.

Metabolic Disorders Rare Diseases

Chugai Pursues Alecensa Patent Infringement Charges In India

Roche affiliate Chugai has moved court in India seeking to restrain Natco and MSN Laboratories over alleged infringement of its patent concerning Alecensa. The Indian firms, however, contend their actions fall under the ambit of the country’s “Bolar exemption” provision.

India Intellectual Property

Finance Watch: Two New VC Funds Raise $955m To Back Life Science Companies

Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.

Financing Innovation

How The Pandemic Changed Deal-Making Between Biotechs And Big Pharma

Speakers on a panel about health care deal-making discussed the influx of capital into biotech during the past two years, how that has impacted deal-making and whether those changes will last.

Deals Business Strategies
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Latest From Policy & Regulation

Stock Watch: Summit’s Stock Plummets

What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.

Stock Watch Clinical Trials

UK Travel Rule Sparks Row As India Seeks To Resume COVID-19 Vaccine Diplomacy

As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.

Policy Coronavirus COVID-19

Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?

Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.

Gene Therapy Reimbursement
See All

Research & Development

Set Alert for Research & Development

Latest From Research & Development

Stock Watch: Summit’s Stock Plummets

What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.

Stock Watch Clinical Trials

AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal

VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.

Companies Research & Development

Looking Past Aduhelm, Biogen Puts Pipeline On Display

In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.

Business Strategies Clinical Trials
See All
UsernamePublicRestriction

Register